LGND Ligand Pharmaceuticals Incorporated
Healthcare$229.33+3.22%ClosedMarket Cap: $4.60B
As of 2026-05-25
Valuation
P/E (TTM)
32.83
PEG
0.01
P/B
4.57
P/S
16.74
EV/EBITDA
19.43
DCF Value
$42.64
FCF Yield
2.7%
Div Yield
0.0%
Margins & Returns
Gross Margin
98.6%
Operating Margin
36.7%
Net Margin
55.9%
ROE
16.2%
ROA
10.0%
ROIC
5.6%
Income Statement
Periods shown are fiscal year quarters (may differ from calendar year)
| Period | Revenue | Gross Margin | Operating Income | Net Income | EPS | Dividend |
|---|---|---|---|---|---|---|
| Q1 null | $51.7M | 96.0% | $17.4M | $-13.3M | $— | — |
| Q4 null | $59.7M | 143.6% | $20.0M | $44.8M | $— | — |
| FY null | $268.1M | 97.5% | $47.2M | $124.5M | $— | — |
| Q3 null | $115.5M | 78.5% | $54.9M | $117.3M | $— | — |
| Q2 null | $47.6M | 93.9% | $8.4M | $4.8M | $— | — |
| Q1 null | $45.3M | 89.3% | $-36.2M | $-42.5M | $— | — |
| Q4 null | $42.8M | 93.4% | $-9.6M | $-31.1M | $— | — |
| FY null | $167.1M | 93.4% | $-22.6M | $-4.0M | $— | — |
| Q3 null | $51.8M | 75.9% | $3.1M | $-7.2M | $— | — |
| Q2 null | $41.5M | 136.9% | $-19.1M | $-51.9M | $— | — |
| Q1 null | $31.0M | 64.3% | $3.0M | $86.1M | $— | — |
| Q4 2023 | $28.1M | 94.1% | $-3.4M | $18.2M | $1.03 | — |